Last updated 2/17/25
Still waiting on that creatinine before giving IV contrast? Let’s dive into the evidence to see if we’re delaying important diagnostic workups unnecessarily.
American College of Radiology (ACR) Recommendations
ACR Contrast Media Manual 2024 is an updated comprehensive guide from the American College of Radiology detailing the safe use of contrast media. Their recommendations on IV contrast and AKI are summarized in the FAQ below.
CA-AKI is a general term used to describe a sudden decline in kidney function that occurs within 48 hours of receiving intravenous iodinated contrast. PC-AKI is a correlative diagnosis, meaning that the contrast may not be the direct cause of kidney injury. The ACR emphasizes that CI-AKI is a sudden deterioration in renal function that is caused by the intravascular administration of iodinated contrast medium;CI-AKI is a subgroup of CA-AKI and a causative diagnosis.
The risk of CA-AKI is generally low, but it is higher in patients with pre-existing risk factors. “At the current time, it is the position of the ACR that CI-AKI is a real, albeit rare entity. Published studies on CI-AKI have been heavily contaminated by bias and conflation. Future investigations building on recent methodological advancements are necessary to clarify the incidence and significance of this disease.”
Routine testing for all patients is not recommended. However, the ACR recommends using screening to identify at-risk patients who might need a serum creatinine measurement before IV contrast. This includes CKD, history of AKI, dialysis, kidney surgery or ablation, albuminuria, diabetes, and metformin use.
ACR stress that the benefits of a contrast-enhanced study often outweigh the risks in life-saving situations. In such cases, it is generally recommended to proceed with contrast administration, even in high-risk patients, while taking precautions to minimize the risk of CI-AKI.
Intravenous hydration with isotonic fluids, such as 0.9% normal saline, is a cornerstone of CA-AKI prevention, particularly for patients with AKI or severe CKD (eGFR less than 30 mL/min/1.73 m2). Prophylaxis typically starts one hour before the exam and continues for 3-12 hours after.
CA/CI-AKI: A Real Phenomenan or a Product of Statistical Bias?
There has been robust literature debunking the myth of contrast associated or induced acute kidney injury. Please review below.
Hinson et al. conducted a retrospective cohort study of 17,934 ED patients over five years to determine whether IV contrast in CT scans increases the risk of acute kidney injury (AKI). They found no significant difference in AKI rates among patients who underwent contrast-enhanced CT, non-contrast CT, or no CT at all (OR 0.96; 95% CI 0.85–1.08), with no association with new chronic kidney disease, dialysis, or renal transplant. These findings support the growing body of evidence suggesting that IV contrast does not independently increase AKI risk—even in patients with preexisting renal dysfunction. Critical appraisals from emDocs and Core EM reinforce this conclusion, noting that many earlier studies linking IV contrast to AKI may suffer from confounding bias, as they often involve sicker patients more likely to have serial creatinine checks. Both sources emphasize that the perceived risk of contrast-induced nephropathy is likely overstated and argue that clinically indicated contrast-enhanced imaging should not be withheld solely due to concerns about AKI.
FOAMed analyses:
- emDOCs: Contrast-Induced Nephropathy: Confounding Causation (by Dr. Rich Sinert)
- Core EM: Acute Kidney Injury is not Associated with IV Contrast Use in the ED
Aycock et al. conducted a meta-analysis published in Annals of Emergency Medicine examining the relationship between IV contrast use during CT scans and the risk of acute kidney injury (AKI). Analyzing data from 28 observational studies with over 107,000 patients, they found no significant difference in AKI rates between those who received contrast-enhanced CT and those who did not (OR 0.94; 95% CI 0.83–1.07). There was also no increased risk of requiring renal replacement therapy (OR 0.83; 95% CI 0.59–1.16) or of mortality (OR 1.00; 95% CI 0.73–1.36). These findings challenge long-held concerns about contrast-induced nephropathy (CIN), suggesting that IV contrast does not significantly contribute to AKI, even in patients with underlying renal disease. Supporting analyses from Core EM, REBEL EM, and SGEM echo this conclusion, emphasizing that AKI risk is likely driven more by patient-related factors than by contrast itself. Core EM highlights that contrast did not increase AKI risk in high-risk populations; REBEL EM questions whether withholding contrast-enhanced imaging is justified; and SGEM notes that modern low- and iso-osmolar contrast agents have dramatically reduced nephrotoxicity. Collectively, these insights argue that IV contrast should not be withheld when clinically indicated, as the historical fear of CIN is not supported by contemporary evidence.
FOAMed analyses
A 2019 retrospective study by Hinson et al. evaluated the risk of AKI following intravenous contrast administration in septic emergency department patients. Analyzing 4,171 patient visits, the study found no significant difference in AKI incidence between those receiving contrast-enhanced CT scans and those who did not. Specifically, AKI occurred in 7.2% of the contrast group versus 9.7% in the non-CT group, with an odds ratio of 0.93 (95% CI 0.71–1.20). These findings suggest that IV contrast may not increase AKI risk in septic patients.
FOAMed analysis
In a 2020 study published in Chest, Williams et al. conducted a propensity-matched analysis to assess the relationship between intravenous contrast administration and acute kidney injury (AKI) in critically ill patients. The study found no significant association between contrast exposure and the development of AKI, suggesting that the use of IV contrast in this population may be safer than previously believed.
FOAMed Analysis:
A 2021 cohort study by Goulden et al. investigated the impact of intravenous radiocontrast on kidney function in emergency department patients undergoing D-dimer testing. Utilizing a regression discontinuity design with a sample of 156,028 individuals, the study found that exposure to intravenous contrast was associated with a 0.4 mL/min/1.73 m² reduction in estimated glomerular filtration rate (eGFR) up to six months post-exposure, a change deemed neither statistically significant nor clinically meaningful. These findings suggest that intravenous contrast does not contribute to significant long-term kidney injury
FOAMed
- JournalFeed: Is IV Contrast Nephrotoxic? Best Study Yet Finds…
- First10 EM: Does contrast cause kidney injury? The evidence
- PulmCrit IBCC: Contrast Nephropathy, myth thereof
- Rebel EM: Kidneys and Contrast
- First10EM: Canadian Guidelines on Contrast-Associated AKI (2022)
IV Prehydration before CT - An Unnecessary Delay
Can you prevent something that doesn’t exist?
The Amacing Trial was a randomized, non-inferiority study that evaluated whether prophylactic IV hydration prevents contrast-induced nephropathy (CIN) in high-risk patients undergoing elective contrast procedures. In 660 patients with moderate renal impairment (eGFR 30–59 mL/min/1.73m²), CIN incidence was nearly identical between the hydration (2.7%) and no hydration (2.6%) groups (absolute difference: -0.1%; 95% CI: -2.25% to 2.06%; p = 0.47). Moreover, the no hydration group was significantly more cost-effective (€792 vs. €1,455), suggesting that routine IV hydration may be unnecessary in this population. The Bottom Line emphasizes that the study's rigorous design supports this conclusion, showing that withholding hydration was both safe and economically advantageous. REBEL EM echoes these findings, noting that the AMACING trial challenges current guidelines recommending prophylactic hydration in high-risk patients. They highlight that avoiding unnecessary fluid administration may reduce complications such as fluid overload and heart failure, marking a potential paradigm shift in the management of contrast administration for patients with moderate CKD.
FOAMed Analyses
- The Bottom Line: AMACING Trial (2017)
- Rebel EM: The AMACING Trial: Prehydration to Prevent Contrast Induced Nephropathy (CIN)?
The KOMPAS trial was a multicenter, noninferiority randomized controlled trial that evaluated whether prophylactic sodium bicarbonate prehydration reduces the risk of postcontrast acute kidney injury (PC-AKI) in stage 3 CKD patients undergoing elective contrast-enhanced CT. Among 523 patients, the incidence of PC-AKI was 2.7% in the no-prehydration group versus 1.5% in the prehydration group (RR 1.7; 95% CI: 0.5–5.9; p = 0.36), with no significant difference in serum creatinine changes. Notably, no patients required dialysis or developed acute heart failure, and healthcare costs were lower in the no-prehydration group. These findings support a more efficient and simplified approach to contrast administration in CKD patients. REBEL EM highlights that the KOMPAS trial directly challenges existing guidelines recommending routine prehydration, showing that it may be unnecessary in stable CKD patients. The trial’s robust design and results suggest that the longstanding concern over contrast nephrotoxicity may be overstated, particularly with the use of modern low-osmolar contrast agents, and that reflexive prehydration strategies may warrant reevaluation to improve patient care and reduce unnecessary interventions.
FOAMed Analysis
Conclusion: Don’t Let Outdated Fears Delay Life-Saving Imaging
The overwhelming body of evidence makes it clear: IV contrast should never be withheld when clinically indicated in the emergency department. The long-standing concern over contrast-induced nephropathy (CIN) has been largely debunked, with multiple high-quality studies and meta-analyses showing no significant increase in AKI risk, even in high-risk patients like those with CKD, sepsis, or critical illness. Additionally, prophylactic prehydration protocols add unnecessary delays and costs without proven benefit, further reinforcing the need to rethink outdated practices. ED physicians must prioritize timely, accurate diagnoses over baseless fears of nephrotoxicity, ensuring that patients receive the best possible care without unnecessary restrictions on essential imaging.
Sources
- Aycock, R. D., Westafer, L. M., Boxen, J. L., Majlesi, N., Schoenfeld, E. M., & Bannuru, R. R. (2018). Acute Kidney Injury After Computed Tomography: A Meta-analysis. Annals of Emergency Medicine, 71(1), 44–53.e4. https://doi.org/10.1016/j.annemergmed.2017.05.027
- Goulden, R., Rowe, B. H., Abrahamowicz, M., Strumpf, E., & Tamblyn, R. (2021). Association of Intravenous Radiocontrast With Kidney Function: A Regression Discontinuity Analysis. JAMA Internal Medicine, 181(6), 767–774. https://doi.org/10.1001/jamainternmed.2021.0916
- Hinson, J. S., Al Jalbout, N., Ehmann, M. R., Klein, E. Y., & Shaw-Smith, C. (2019). Acute kidney injury following contrast media administration in the septic patient: A retrospective propensity-matched analysis. Journal of Critical Care, 51, 111–116. https://doi.org/10.1016/j.jcrc.2019.02.003
- Hinson, J. S., Ehmann, M. R., Fine, D. M., Fishman, E. K., Toerper, M. F., Rothman, R. E., & Klein, E. Y. (2017). Risk of Acute Kidney Injury After Intravenous Contrast Media Administration. Annals of Emergency Medicine, 69(5), 577–586.e4. https://doi.org/10.1016/j.annemergmed.2016.11.021
- Nijssen, E. C., Rennenberg, R. J., Nelemans, P. J., Essers, B. A., Janssen, M. M., Vermeeren, M. A., van Ommen, V., Wildberger, J. E., & Kessels, A. G. (2017). Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. The Lancet, 389(10076), 1312–1322. https://doi.org/10.1016/S0140-6736(17)30057-0
- Timal, R. J., Kooiman, J., Sijpkens, Y. W., de Vries, J. P., Verberk-Jonkers, I. J., Brulez, H. F., van Buren, M., van der Molen, A. J., Cannegieter, S. C., Putter, H., & Willems, H. C. (2020). Effect of No Prehydration vs Sodium Bicarbonate Prehydration Prior to Contrast-Enhanced Computed Tomography in the Prevention of Postcontrast Acute Kidney Injury in Adults With Chronic Kidney Disease: The Kompas Randomized Clinical Trial. JAMA Internal Medicine, 180(4), 533–541. https://doi.org/10.1001/jamainternmed.2019.7428
- Williams, L. S., Walker, G. R., Loewenherz, J. W., & Gidel, L. T. (2020). Association of Contrast and Acute Kidney Injury in the Critically Ill: A Propensity-Matched Study. Chest, 157(4), 866–876. https://doi.org/10.1016/j.chest.2019.10.005
This post is for education only and not medical advice.